SCHEMBL647992

SCHEMBL647992

Cc1cccc(-c2ccccc2)n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.68
RAB9A P51151 5/20 0.68
KMT2A Q03164 5/20 0.68
CCR1 P32246 1/20 0.68
CCR8 P51685 1/20 0.68
CYP2A6 P11509 1/20 0.62
TGFBR1 P36897 1/20 0.56
ASIC3 Q9UHC3 1/20 0.56
NPC1 O15118 3/20 0.49
ATM Q13315 1/20 0.49
METAP2 P50579 1/20 0.47
ALDH1A1 P00352 5/20 0.46
ADORA1 P30542 2/20 0.44
NOS3 P29474 1/20 0.44
NOS2 P35228 1/20 0.44
ADORA2A P29274 1/20 0.44
KDM4E B2RXH2 3/20 0.44
PKM P14618 3/20 0.44
GRM5 P41594 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29963679 1.00 MEN1 (0.68) MEN1RAB9AKMT2ACCR1CCR8
Bromide SCHEMBL15901554 0.98 RAB9A (0.65) MEN1RAB9AKMT2ACCR1CCR8
SCHEMBL12594495 0.98 MEN1 (0.64) MEN1RAB9AKMT2ACCR1CCR8
SCHEMBL2189142 0.96 KMT2A (0.62) MEN1RAB9AKMT2ACCR1CCR8
SCHEMBL3422361 0.90 CCR1 (0.75) MEN1RAB9AKMT2ACCR1CCR8
SCHEMBL16189026 0.90 MEN1 (0.56) MEN1RAB9AKMT2ACCR1CCR8
SCHEMBL16189330 0.88 MEN1 (0.54) MEN1RAB9AKMT2ACCR1CCR8
SCHEMBL16189443 0.88 MEN1 (0.54) MEN1RAB9AKMT2ACCR1CCR8
SCHEMBL17932287 0.88 MEN1 (0.54) MEN1RAB9AKMT2ACCR1CCR8
SCHEMBL19009229 0.87 CCR1 (0.58) MEN1RAB9AKMT2ACCR1CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 896 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025132825-A1 1H-IMIDAZO[4,5-C]QUINOLINE METAL-BASED COMPLEXES USEFUL AS MEDICAMENTS FUNDACIÓN DONOSTIA INTERNATIONAL PHYSICS CENTER - DIPC (ES) 2025-06-26 WO claimed
CN-107407878-B Photosensitive resin composition 东丽株式会社 2020-11-17 CN claimed
EP-3089980-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2018-01-31 EP claimed
EP-2119717-B1 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors BOEHRINGER INGELHEIM INT (DE) 2018-01-17 EP claimed
US-9670208-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2017-06-06 US claimed
EP-3089980-A1 SERINE/THREONINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2016-11-09 EP claimed
US-20160304519-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-10-20 US claimed
WO-2015103137-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2015-07-09 WO claimed
US-8697868-B2 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-04-15 US claimed
US-20090137801-A1 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-28 US claimed
EP-1758905-B1 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR BOEHRINGER INGELHEIM INT (DE) 2009-04-29 EP claimed
US-7501426-B2 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-03-10 US claimed
CN-1894269-A Metal complexes with bipodal ligands MERCK PATENT GMBH (DE) 2007-01-10 CN claimed
US-20050234108-A1 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-20 US claimed
US-20260098105-A1 PREPOLYMERIZED CATALYST FOR OLEFIN POLYMERIZATION, METHOD OF PRODUCING THIS PREPOLYMERIZED CATALYST AND METHOD OF PRODUCING OLEFIN POLYMER WITH IMPROVED PROCESSABILITY AND OPTICAL PROPERTIES FORMOSA PLASTICS CORPORATION, U.S.A. (US) 2026-04-09 US disclosed
WO-2025217072-A1 HIGH DART IMPACT AND TEAR FILMS FROM TITANIUM BASED PREPOLYMER CATALYZED POLYETHYLENES FORMOSA PLASTICS CORPORATION, USA (US) 2025-10-16 WO disclosed
WO-2025132825-A1 1H-IMIDAZO[4,5-C]QUINOLINE METAL-BASED COMPLEXES USEFUL AS MEDICAMENTS FUNDACIÓN DONOSTIA INTERNATIONAL PHYSICS CENTER - DIPC (ES) 2025-06-26 WO disclosed
US-4220781-A QUARTINIZATION, REARRANGEMENT AND REDUCTION PHILIP MORRIS, INC. (US) 1980-09-02 US disclosed
US-4155909-A INSECTICIDES PHILIP MORRIS INCORPORATED (US) 1979-05-22 US disclosed
EP-0000106-A1 2-Alkyl nicotinoids and processes for their production and use PHILIP MORRIS INCORPORATED (US) 1978-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098105-A1 PREPOLYMERIZED CATALYST FOR OLEFIN POLYMERIZATION, METHOD OF PRODUCING THIS PREPOLYMERIZED CATALYST AND METHOD OF PRODUCING OLEFIN POLYMER WITH IMPROVED PROCESSABILITY AND OPTICAL PROPERTIES DIS3, DRD4, SRP54 MEN1 1557/4885RAB9A 1767/4885KMT2A 3899/4885
US-20160304519-A1 SERINE/THREONINE KINASE INHIBITORS TTBK1, MAP3K1, TNNI3K MEN1 746/4885RAB9A 2449/4885KMT2A 2696/4885
US-20090137801-A1 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS DPP8, DPP4, DPP7 MEN1 4401/4885RAB9A 2812/4885KMT2A 2927/4885
US-20050234108-A1 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions DPP8, DPP4, DPP7 MEN1 3845/4885RAB9A 2916/4885KMT2A 3131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.